Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that phytosterols extracted from moringa seed oil may act as potential anti-alopecia agents by inhibiting the 5α-reductase enzyme, with ergostadienol showing particularly high affinity and stability in in silico simulations.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This study found that arginine vasotocin is evolutionarily conserved across diverse taxa and may play roles in neuroendocrine, immune, and stress signaling, with potential antimicrobial applications.

This review discusses 5-alpha reductase inhibitors, highlighting their long-term efficacy and tolerability in treating benign prostate hyperplasia, while also noting sexual dysfunction as a common adverse effect.

This report describes cases of transient thyrotoxicosis potentially linked to oral retinoid treatment, suggesting a possible mechanism involving increased iodine uptake by thyroid cells.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This study reports that spironolactone use was associated with a decreased risk of developing rosacea compared to other diuretics, particularly in current users without previous androgenic skin disease diagnoses.

In this review, the researchers reported that 5α-reductase inhibitors demonstrated neuroprotective effects and reduced dyskinesias in animal models of Parkinson's disease, suggesting their potential for repurposing to manage symptoms in men with PD.

In this case report, a patient with diffuse alopecia areata experienced complete hair regrowth after treatment with oral abrocitinib, with no adverse effects observed.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

This review highlights the potential of amphiregulin as a therapeutic target, noting its role in both fibrotic and malignant diseases, and discusses promising early findings but reports no new clinical results.

This study found that inhibiting arachidonate 12-lipoxygenase (ALOX12) may enhance hair cuticle maturation by increasing S100A3 protein citrullination and promoting cuticular differentiation in isolated human hair follicles.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.

This study identified serum androsterone as a robust biomarker for monitoring response to AKR1C3 inhibitor treatment in women and found that a 4-week administration of aldo-keto reductase 1C3 inhibitors did not impact ovarian function.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

This study found that D'orenone blocks root hair growth by increasing PIN2 protein abundance, leading to reduced auxin concentration, but external auxin can reverse these effects.

This study utilized a sequence-structure alignment approach to improve the characterization of Class A Rhodopsin GPCR superfamily, including orphan and unclassified receptors, through evolutionary analysis.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study by Gao et al. reports that two nonsteroidal selective androgen receptor modulators, S1 and S4, demonstrated tissue-selective actions in rats, suppressing prostate growth while maintaining muscle growth without altering hormone levels.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

Melatonin may protect inner ear cells from damage by reducing cell death and oxidative stress, potentially treating sudden hearing loss.

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This study found that vitamin A treatment in rats reduced hyperplastic-dysplastic changes and sebaceous gland hypertrophy associated with 3,4-benzpyrene-induced tumors.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.